578 Results

Pivotal phase III data of Bavencio + Inlyta for renal cell carcinoma is published in NEJM.- Merck KGaA + Pfizer

 Added 1 day ago

Merck KGaA and Pfizer Inc. announced the publication of results from an interim analysis of the pivotal JAVELIN Renal 101...

Darolutamide + ADT extends metastasis-free survival in non-metastatic castration-resistant prostate cancer. Bayer HealthCare

 Added 2 days ago

Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant...

Opdivo + Yervoy success in CheckMate 650 trial for prostate cancer. -BMS

 Added 3 days ago

Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer...

Keytruda and Lynparza early findings for treatment of prostate cancer.- Merck Inc.

 Added 4 days ago

Merck Inc., announced the presentation of interim data from the Phase 1b/II KEYNOTE-365 umbrella trial investigating Keytruda, Merck’s anti-PD-1 therapy,...

Phase III ARCHES trial of Xtandi meets primary endpoint in metastatic prostate cancer.- Pfizer Inc. and Astellas

 Added 6 days ago

Pfizer Inc. and Astellas Pharma announced results from the Phase III ARCHES trial of Xtandi (enzalutamide) in men with metastatic...

FDA accepts sBLA for Bavencio + Inlyta combination to treat renal cell carcinoma.- Pfizer + Merck KGaA.

 Added 6 days ago

Merck and Pfizer Inc. announced that the FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for...

Opdivo + Yervoy 30 month results from CHECKMATE 214 study for renal cell carcinoma.- BMS

 Added 6 days ago

Bristol-Myers Squibb Company announced new results from the Phase III CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus...

MK 7655 + Primaxin + cilastatin filed with FDA for cUTI + cIAI.- Merck Inc

 Added 13 days ago

Merck Inc. announced that the FDA has accepted for review regulatory filings for Priority Review for the combination of MK...

Successful phase III TITIAN trial of Erleada for metastatic castration-sensitive prostate cancer. Janssen

 Added 17 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the unblinding of the Phase III TITAN study evaluating Erleada (apalutamide)...

FDA approves Sangia Total Prostate Specific Antigen (PSA) diagnostic Test for prostate cancer.- Opko Health

 Added 17 days ago

Opko Health announced that the FDA has approved the Company’s point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the...

Load more